Shares of Eiger BioPharmaceuticals Inc. EIGR, -7.37% tumbled 20.4% in premarket trading on Wednesday after the company said it will not pursue emergency authorization of its experimental treatment for mild and moderate COVID-19 infections. It had asked the Food and Drug Administration to consider an EUA application based on data from the Together trial, a Phase 3 study that has assessed 11 possible treatments for COVID-19 that is being conducted in Brazil and Canada. Eiger said the FDA instead recommended the company consider running its own pivotal trial for peginterferon lambda that would support full approval of the drug. Eiger’s stock is up 42.4% this year, while the S&P 500 SPX, -1.10% has declined 20.4%.
